Vivoryon Therapeutics N.V.
VVY.AS · AMS
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | €0 | €0 | €0 | -€3,620 |
| % Growth | – | – | 100% | – |
| Cost of Goods Sold | €73 | €74 | €73 | €525 |
| Gross Profit | -€73 | -€74 | -€73 | -€4,145 |
| % Margin | – | – | – | 114.5% |
| R&D Expenses | €2,768 | €3,750 | €10,308 | €11,378 |
| G&A Expenses | €2,755 | €3,399 | €3,501 | €4,164 |
| SG&A Expenses | €2,755 | €3,328 | €3,501 | €4,167 |
| Sales & Mktg Exp. | €0 | €0 | €0 | €3 |
| Other Operating Expenses | €0 | €0 | -€73 | -€475 |
| Operating Expenses | €5,523 | €7,078 | €13,736 | €15,070 |
| Operating Income | -€5,523 | -€7,152 | -€13,809 | -€18,145 |
| % Margin | – | – | – | 501.2% |
| Other Income/Exp. Net | €50 | €143 | €250 | €330 |
| Pre-Tax Income | -€5,473 | -€7,009 | -€13,559 | -€17,815 |
| Tax Expense | €0 | €0 | €0 | -€189 |
| Net Income | -€5,473 | -€7,009 | -€13,559 | -€17,626 |
| % Margin | – | – | – | 486.9% |
| EPS | -0.21 | -0.27 | -0.52 | -0.72 |
| % Growth | 22.2% | 48.1% | 27.8% | – |
| EPS Diluted | -0.21 | -0.27 | -0.52 | -0.72 |
| Weighted Avg Shares Out | 26,130 | 25,979 | 26,067 | 24,522 |
| Weighted Avg Shares Out Dil | 26,130 | 25,979 | 26,067 | 24,522 |
| Supplemental Information | – | – | – | – |
| Interest Income | €74 | €223 | €259 | €380 |
| Interest Expense | €24 | €64 | €22 | €30 |
| Depreciation & Amortization | €43 | €74 | €46 | €43 |
| EBITDA | -€5,480 | -€6,855 | -€13,763 | -€17,502 |
| % Margin | – | – | – | 483.5% |